Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Article Title: Magnetic resonance image-guided brachytherapy for cervical cancer : Prognostic factors for survival.
PMID/MRN: 27734106
Publication Date: 2016-Dec-25
Abstract:
The purpose of this work was to identify prognostic factors for survival after magnetic resonance image (MRI)-guided brachytherapy combined with external beam radiotherapy for cervical cancer.
External beam radiotherapy of 45-50.4ÊGy was delivered by either three-dimensional conformal radiotherapy or helical tomotherapy. Patients also received high-dose-rate MRI-guided brachytherapy of 5ÊGy in 6Êfractions.
We analyzed 128 patients with International Federation of Gynecology and Obstetrics stage IB-IVB cervical cancer who underwent MRI-guided brachytherapy. Most patients (96 %) received concurrent chemotherapy. Pelvic lymph node metastases and para-aortic lymphadenopathies were found in 62 % and 14 % of patients, respectively. The median follow-up time was 44Êmonths. Complete remission was achieved in 119 of 128 patients (93 %). The 5-year local recurrence-free, cancer-specific, and overall survival rates were 94, 89, and 85 %, respectively. Negative pelvic lymphadenopathy, gross tumor volume (GTV) dose covering 90 % of the target (GTV D90) of >110ÊGy, and treatment duration ²56Êdays were associated with better overall survival in univariate analyses. Multivariable analysis showed that GTV D90 of >110ÊGy and treatment duration ²56Êdays were possibly associated with overall survival with near-significant P-values of 0.062 and 0.073, respectively.
The outcome of MRI-guided brachytherapy combined with external beam radiotherapy in patients with cervical cancer was excellent. GTV D90 of >110ÊGy and treatment duration ²56Êdays were potentially associated with overall survival.